VBC SUCCESS IS POSSIBLE. HERE’S HOW.
Get our latest insights and exclusive case studies.
Learn more

Podcast

Ep. 249: What is 340B, and why is it in the hot seat

Many health systems rely on the 340B program for their financial sustainability. But it’s long come under criticism, and now, proposed changes are on the table. Our experts discuss 340B’s evolution and the impact of potential reforms. Plus, get an update on the recent executive order on drug pricing.

The federal drug purchasing program known as 340B was created in 1992 to help select provider organizations stretch scarce resources to care for patients. More than three decades later, health systems of all shapes and sizes have come to rely on 340B for their financial sustainability. But the program has come under criticism. And in recent years, it’s been under more scrutiny, with manufacturers, state governments, and federal regulators proposing changes to how it operates.

In this episode, host Abby Burns invites Advisory Board experts Gina Lohr and Chloe Bakst to unpack the origin and controversy around 340B. They debate whether 340B has strayed from its intended purpose and break down the proposed changes to the program, how likely they are to go into effect, and what those changes would mean for health systems.

Plus, stay tuned to the end of the episode, where co-host Rae Woods discusses the recent healthcare-focused executive order and what it signals for the future of this administration’s drug policy.

Let us know what you think about today’s discussion, or share your ideas for future episode topics by leaving us a voice message or emailing us.

Links:


GLP-1 innovation showcase


A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.


SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece

Email ask@advisory.com to learn more

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This is for members only. Learn more.

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.